Orchestra BioMed (OBIO): Utang-utang marang kapitalisasi buku

Orchestra BioMed (OBIO) develops hybrid therapy systems targeting cardiac surgeons and clinics through its stents and BackBeat devices. The business model relies on patents and a distributor network, ensuring high profitability and rapid growth. This chart reflects current share prices fixed at 2.24. Meanwhile, cardiac system assembly plants are operating normally, implementing laser welding.

The uniqueness of the BackBeat system and support from Medtronic provide Orchestra BioMed (OBIO) with pricing power, which, combined with the current debt-to-equity ratio, allows for an assessment of the business's financial autonomy. This ratio is calculated as total liabilities divided by balance sheet equity, measuring the company's degree of dependence on borrowed funds and determining the overall stability of the financing structure.